The pharmaceutical leader has established itself as the leader in the fast-growing weight loss market. And although many ...

UnitedHealth Group has had a tumultuous year, marred by poor performance and controversy. Eli Lilly has thrived as it's taken ...

Good news for people on GLP-1 therapy who hate needles: Trial data out this week shows that an experimental pill developed by ...

Eli Lilly ( LLY 1.19%) and Novo Nordisk ( NVO 2.44%) are two of the leading companies in the fast-growing GLP-1 weight loss ...

Eli Lilly also said it has filed for Food and Drug Administration approval of the daily GLP-1 pill, called orforglipron, for ...

Lilly has a new pill, called orforglipron, it plans to launch next year. On Thursday, the company reported the results of a ...

On December 16, Daiwa analyst Narumi Nakagiri upgraded Eli Lilly and Company (NYSE:LLY) to Buy from Neutral and set a $1,230 ...

Eli Lilly’s oral pill, orforglipron, helped maintain weight loss in patients switching from injectable versions of GLP-1 ...

According to the study, orforglipron users maintained their weight loss levels more closely after previously taking a rival's ...

At WIRED's Big Interview event, Eli Lilly and Company's Executive Vice President and Chief Information and Digital Officer, ...

In the ATTAIN-MAINTAIN study of its orforglipron candidate, switching to the drug after 72 months of injectable treatment ...

Since 1957, GQ has inspired men to look sharper and live smarter with its unparalleled coverage of style, culture, and beyond ...